Lever
Lifestyle
- Regular monitoring of coagulation status
- Avoiding unnecessary use of anticoagulants
- Managing underlying health conditions
Blutwerte · Marker
aPTT
Activated Partial Thromboplastin Time · PTT
Gerinnung
- Einheit:
- seconds
aPTT quantifies the time taken for blood plasma to clot via the intrinsic and common coagulation pathways.
Reference Ranges
Reference
25–35seconds
25
35
LowNormalHigh
Reference
Unit · secondsReference ranges may vary slightly between laboratories due to different reagents and equipment.
Overview
Übersicht
Activated Partial Thromboplastin Time (aPTT) is a laboratory test that measures the efficacy of the intrinsic and common coagulation pathways by evaluating the time it takes for a clot to form in a plasma sample after the addition of calcium and phospholipids. Researchers observed that aPTT is crucial for monitoring anticoagulation therapy, particularly with unfractionated heparin (UFH), as it reflects the activity of several clotting factors including factors VIII, IX, XI, and XII. Clinically, aPTT is used to assess bleeding disorders, such as hemophilia, and to investigate prolonged clotting times which may indicate factor deficiencies or the presence of inhibitors. In the context of athletic performance and biohacking, aPTT may not have direct relevance, but understanding coagulation status can be important for individuals engaged in activities with a high risk of injury or those using anticoagulant therapies. Researchers found that aPTT results can be influenced by various factors, including the type of reagents used, biological variability, and pre-analytical conditions such as sample handling. Therefore, it is crucial to interpret aPTT values in conjunction with clinical findings and other laboratory tests.
Klinische Bedeutung
Elevated aPTT values may indicate bleeding disorders, such as hemophilia or the presence of coagulation inhibitors, while reduced values are less common but may suggest hypercoagulable states.
Dynamics
Trend Interpretation
Rising Values
Progressively rising aPTT values suggest increased bleeding risk; retest and evaluate for possible factor deficiencies or inhibitors.
Falling Values
Progressively falling aPTT values may indicate reduced anticoagulation effect, requiring adjustment of therapy.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Hemophilia
- Liver disease
- Vitamin K deficiency
- Presence of lupus anticoagulant
- Heparin therapy
Cause
Low Levels
- Technical error
- Sample contamination
- Shortened due to high factor VIII levels
- Hypercoagulable states
Protocol
How to Optimize
Lever
Nutrition
- Adequate vitamin K intake
- Balanced diet to support liver function
Note:
Consult a healthcare provider before making changes to anticoagulation therapy or diet.
Testing Guidelines
✓Fasting Not Required
✓Not Time-Sensitive
Testing Frequency
As needed for anticoagulation therapy monitoring or bleeding disorder diagnosis.
Interfering Factors
- Improper sample handling
- Use of certain medications
- Recent blood transfusion
Open Research Questions
Current research suggests that the variability in aPTT readings across different laboratories and reagents remains a significant concern, with no standardized reference ranges established for optimal monitoring of unfractionated heparin. Researchers have not yet established the most effective protocols for interpreting mixing studies to differentiate between factor deficiencies and inhibitors. Additionally, clinical questions remain unanswered regarding the impact of biologic factors on aPTT results and the long-term outcomes of transitioning to antifactor Xa monitoring.
24 Research Publications
711
Total Citations
5
Human/RCT
3.0
Avg. Influence
2025
Latest
Sort
Filter
01Top
#01
Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
ReviewInfluence5.0
225
This study examined the effectiveness of monitoring unfractionated heparin (UFH) using activated partial thromboplastin time (aPTT) compared to antifactor Xa levels. Researchers found that antifactor Xa monitoring may provide more stable results with fewer required adjustments, making it a cost-effective alternative. The study discusses the advantages and disadvantages of both methods for optimizing UFH monitoring.
02Top
#02
Laboratory testing of anticoagulants: the present and the future.
ReviewInfluence6.0
111
This review provided an update on laboratory testing for anticoagulants, including activated partial thromboplastin time (aPTT). Researchers discussed the benefits and limitations of current tests and highlighted the need for proactive development of strategies for monitoring new anticoagulants, despite the ongoing use of traditional tests.
03Top
#03
Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
Marlar Richard A, et al. · Seminars in thrombosis and hemostasis · 2017
ReviewInfluence4.0
78
Researchers reviewed the challenges of monitoring unfractionated heparin therapy using aPTT. They highlighted the variability in aPTT results due to patient factors and reagent differences. The study provided recommendations for establishing a consistent therapeutic range for aPTT in various hospital settings.
Key findings
- 01Researchers observed that the APTT test is commonly used but only estimates heparin concentration.
- 02They noted that patient differences and test conditions can affect APTT results.
- 03The article suggests ways for laboratories to better establish heparin therapeutic ranges.
04
#04
Therapeutic monitoring of unfractionated heparin - trials and tribulations.
ReviewInfluence3.0
55
This study explored the challenges in therapeutic monitoring of unfractionated heparin (UFH), noting the variability in activated partial thromboplastin time (aPTT) results. Researchers found that while aPTT is widely used, its relevance to current laboratory practices is limited, and alternative monitoring methods may be more effective.
05
#05
Laboratory investigations for bleeding disorders.
ReviewInfluence3.0
48
Researchers explored the effectiveness of coagulation tests, including aPTT, in detecting bleeding disorders. They found that while these tests have high specificity, their sensitivity for clinically significant abnormalities is low. The study suggests that expanding testing panels may improve detection rates for bleeding disorders.
06
#06
Coagulation in Liver Disease.
Review
39
Researchers discussed the liver's role in hemostasis, noting that standard tests like aPTT and PT do not fully reflect coagulation status in liver disease. The study emphasized that these tests may not accurately predict bleeding or thrombosis risks in patients with liver failure.
07
#07
COVID-19-related laboratory coagulation findings.
Devreese Katrien M J · International journal of laboratory hematology · 2021
ReviewInfluence1.0
38
This article examined coagulation findings in COVID-19 patients, noting significant alterations in hemostatic balance. Researchers found that elevated D-dimer levels and derangements in aPTT, among other markers, indicate a high risk of thrombosis. The study suggested that while aPTT may be affected, it is not currently used for diagnosis or management in COVID-19.
Key findings
- 01Researchers found that COVID-19 patients have a high prothrombotic status, increasing their risk of blood clots.
- 02Elevated D-dimer levels serve as a crucial marker for assessing thrombosis risk in these patients.
- 03Other coagulation parameters may indicate changes in blood clotting but are not yet standard for diagnosis or management.
08
#08
Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review.
ReviewInfluence2.0
28
This mini-review addressed the interpretation of unexpected isolated prolonged aPTT. Researchers found that this condition can indicate various issues, including lupus anticoagulants or factor deficiencies. The study provided a diagnostic algorithm to help differentiate between these causes, emphasizing the importance of accurate diagnosis for effective management.
09
#09
Activated Partial Thromboplastin Time and Prothrombin Time Mixing Studies: Current State of the Art.
ReviewInfluence2.0
25
This study reviewed the use of mixing studies to investigate prolonged activated partial thromboplastin time (aPTT) and prothrombin time (PT). Researchers found that mixing studies can help differentiate between factor deficiencies and inhibitors, although there is a lack of standardization in testing protocols. The review highlights the importance of understanding preanalytic variables that may affect test performance.
10
#10
Coagulation.
Review
19
This article provided an overview of the limitations of coagulation tests, including aPTT and PT. Researchers noted that these tests only assess the coagulation protein compartment and must be interpreted in context with clinical symptoms. The study emphasized that routine preoperative screening using these tests is often unnecessary without a history of bleeding.
Clinical Trials (2)
2
Total Trials
172
Total Enrolled
Effects of Tourniquet Applied During Total Knee Replacement Surgery on Patient Hemodynamics and Blood Table
NCT07002086COMPLETED
Sponsor
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
Enrollment
22
Started
2025
Primary outcome
Activated Partial Thromboplastin Time(APTT)
Primary Gonarthrosis
DetectIon of Severe Sepsis In PATients With Neurological haemorrhagE (The DISSIPATE Study)
NCT04624945UNKNOWN
Sponsor
National University Hospital, Singapore
Enrollment
150
Started
2020
Primary outcome
To validate the use of APTT CWA and ICIS, as early sepsis markers for neurosurgical ICU patients suffering subarachnoid haemorrhage, traumatic brain injury and other intracranial haemorrhages.
SepsisHemorrhage Brain
Publication Trend
Research publications about aPTT over time
10totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer